HilleVax, Inc. (NASDAQ:HLVX - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for HilleVax in a research note issued to investors on Monday, March 31st. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright has a "Neutral" rating and a $2.00 price objective on the stock. The consensus estimate for HilleVax's current full-year earnings is ($2.64) per share. HC Wainwright also issued estimates for HilleVax's Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.24) EPS.
HilleVax Price Performance
Shares of HLVX stock traded up $0.06 on Thursday, reaching $1.46. 114,915 shares of the company were exchanged, compared to its average volume of 194,501. The company has a 50-day moving average of $1.76 and a 200-day moving average of $1.85. The company has a market cap of $72.96 million, a price-to-earnings ratio of -0.47 and a beta of 0.86. HilleVax has a one year low of $1.34 and a one year high of $16.31.
HilleVax (NASDAQ:HLVX - Get Free Report) last issued its earnings results on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02).
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of HilleVax during the fourth quarter valued at approximately $13,919,000. Lightspeed Management Company L.L.C. acquired a new stake in HilleVax in the 4th quarter valued at $4,847,000. JPMorgan Chase & Co. increased its stake in HilleVax by 1,376.8% during the 4th quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company's stock valued at $429,000 after purchasing an additional 193,124 shares in the last quarter. Verition Fund Management LLC acquired a new position in HilleVax during the third quarter worth $331,000. Finally, Millennium Management LLC lifted its stake in shares of HilleVax by 59.6% in the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock valued at $852,000 after buying an additional 153,815 shares in the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.
HilleVax Company Profile
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Featured Articles
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
